Short Interest in HCW Biologics Inc. (NASDAQ:HCWB) Increases By 59.8%
by Scott Moore · The Cerbat GemHCW Biologics Inc. (NASDAQ:HCWB – Get Free Report) saw a large growth in short interest during the month of January. As of January 15th, there was short interest totaling 21,438 shares, a growth of 59.8% from the December 31st total of 13,416 shares. Approximately 1.1% of the company’s shares are sold short. Based on an average trading volume of 42,653 shares, the short-interest ratio is currently 0.5 days. Based on an average trading volume of 42,653 shares, the short-interest ratio is currently 0.5 days. Approximately 1.1% of the company’s shares are sold short.
Analyst Ratings Changes
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of HCW Biologics in a report on Thursday, January 22nd. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, HCW Biologics currently has a consensus rating of “Hold” and a consensus target price of $35.00.
Get Our Latest Analysis on HCWB
Institutional Investors Weigh In On HCW Biologics
An institutional investor recently bought a new position in HCW Biologics stock. Golden State Wealth Management LLC purchased a new position in shares of HCW Biologics Inc. (NASDAQ:HCWB – Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 10,000 shares of the company’s stock, valued at approximately $40,000. Golden State Wealth Management LLC owned 0.69% of HCW Biologics at the end of the most recent quarter. Hedge funds and other institutional investors own 2.96% of the company’s stock.
HCW Biologics Stock Performance
Shares of HCWB traded up $0.04 during trading hours on Monday, hitting $1.15. The stock had a trading volume of 15,174 shares, compared to its average volume of 65,753. HCW Biologics has a 12-month low of $0.95 and a 12-month high of $41.20. The firm has a market cap of $3.76 million, a P/E ratio of -0.09 and a beta of 0.71. The company’s fifty day simple moving average is $1.52 and its 200 day simple moving average is $3.16.
HCW Biologics (NASDAQ:HCWB – Get Free Report) last announced its quarterly earnings results on Friday, November 14th. The company reported ($2.02) EPS for the quarter, missing the consensus estimate of $1.58 by ($3.60). The business had revenue of $0.00 million during the quarter, compared to the consensus estimate of $7.00 million.
HCW Biologics Company Profile
HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.